Use of Cardiomyocytes for the Assessment of Proarrhythmic Risk, Oct. 25–26: Abstract Deadline Sept. 30

The Society of Toxicology Contemporary Concepts in Toxicology (SOT CCT) conference on The Use of Cardiomyocytes for the Assessment of Proarrhythmic Risk will be held October 25–26, 2016, in Arlington, Virginia. The abstract submission deadline is September 30, 2016.

Human stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly used in drug discovery, toxicity assessment, and cell-based disease treatment. In vitro screening assays also are used to make decisions about which drug candidates to progress into development. In light of the potential utility of this emergent technology, this workshop will engage experts in presenting and discussing various aspects of the phenotype of these cells (functional, proteins, biochemical) and comparing them to adult ventricular CMs, as a basis for assessing their potential uses in drug and chemical safety testing. This workshop will include domestic and international scientists from government agencies, pharmaceutical industry, and academia to discuss the current state of the art and the path forward.

Through the Teratology Society's membership in the Scientific Liaison Coalition, Teratology Society members are eligible for a discounted registration rate. If you register for this conference, make sure to select the SLC rate for your registration!

For more information, to submit an abstract, and to register, please visit the conference website.

Recent Stories
Announcing the New Teratology Society Innovator Award

FDA Launches Predictive Toxicology Roadmap

PODCAST: Secrets of the Human Brain Revealed: Development, Disease & the Zika Virus